We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
- Authors
Colao, Annamaria; Auriemma, Renata S; Galdiero, Mariano; Lombardi, Gaetano; Pivonello, Rosario
- Abstract
<bold>Objective: </bold>The objective of the study was to evaluate the efficacy of 5 yr of depot somatostatin analogs (SSAs) as first-line therapy in acromegaly.<bold>Outcome Measures: </bold>Primary measures were fasting GH 2.5 microg/liter or less and IGF-I normalized for age and tumor shrinkage. Secondary measures were control of hypertension, arrhythmias, left ventricular hypertrophy, diastolic and systolic dysfunction, and change in lipid and glucose profile.<bold>Patients: </bold>Patients included 45 de novo patients (18 women and 27 men, aged 20-82 yr); 28 were treated with octreotide-long-acting release and 17 with lanreotide.<bold>Results: </bold>GH was controlled in 100% and IGF-I levels in 97.8%, tumor shrinkage was 74.9 +/- 22.1 and 78.2+/-14.5%, in the octreotide-long-acting release and lanreotide groups, respectively. There was a significant improvement in the prevalence of hypertension (from 46.7 to 22.2%, P = 0.027), arrhythmias (from 17.8% to zero, P = 0.01), left ventricular hypertrophy (from 82.2 to 42.2%, P < 0.0001), diastolic dysfunction (from 60.0 to 15.6%, P < 0.0001), systolic dysfunction (from 40.0 to 4.4%, P < 0.0001), and hypertriglyceridemia (from 40.0 to 4.4%, P < 0.0001). The prevalence of impaired glucose tolerance (IGT; from 28.9 to 20.0%. P = 0.46) and diabetes mellitus (from 22.4 to 31.1%, P = 0.64) did not change.<bold>Conclusions: </bold>In patients with severe comorbidities and those who refuse surgery, 5 yr of exclusive SSA therapy induce successful control of GH and IGF-I; tumor shrinkage (by median 80%), and improvement of hypertension, cardiac performance; and dyslipidemia. No patient was withdrawn from treatment because of side effects, and glucose tolerance was stable. We suggest that first-line SSA treatment may be safely continued in patients with acromegaly, according to an individual patient's indications and preferences.
- Subjects
ANTINEOPLASTIC agents; PEPTIDES; OCTREOTIDE acetate; ACROMEGALY; COMPARATIVE studies; CONTROLLED release preparations; LONGITUDINAL method; RESEARCH methodology; MEDICAL cooperation; NEUROSURGERY; PITUITARY tumors; RESEARCH; SOMATOMEDIN; SOMATOSTATIN; EVALUATION research; HUMAN growth hormone; TREATMENT effectiveness; DISEASE complications; THERAPEUTICS
- Publication
Journal of Clinical Endocrinology & Metabolism, 2009, Vol 94, Issue 10, p3746
- ISSN
0021-972X
- Publication type
journal article
- DOI
10.1210/jc.2009-0941